IP Library Granted Patent US 10,539,559
Granted Patent B2
US 10,539,559 · App. 14/420,122 · Granted Jan 21, 2020

PIVKA-II measurement method, measurement reagent, and measurement kit

Inventors: Kentaro Yamaguchi (Tokyo, JP); Katsumi Aoyagi (Tokyo, JP); Azusa Terao (Tokyo, JP)
Assignees: FUJIREBIO INC.; SEKISUI MEDICAL CO., LTD.
G01N33/54306C07K14/745G01N33/57438G01N33/86G01N2333/745
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,539,559
App. No.
14/420,122
Granted
Jan 21, 2020
Kind
B2
Abstract

Disclosed are a PIVKA-II measurement method that achieves better serum-plasma correlation than conventional methods, and a reagent and a kit therefor. The PIVKA-II measurement method according to the present invention comprises measuring PIVKA-II in a sample by an immunoassay using a mixture of an anti-F1 antibody that specifically binds to prothrombin fragment F1 or an antigen-binding fragment thereof and an anti-F2 antibody that specifically binds to prothrombin fragment F2 or an antigen-binding fragment thereof; and an anti-PIVKA-II antibody that specifically binds to PIVKA-II or an antigen-binding fragment thereof.

Claims (11)

1. A method for measuring Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II), comprising:

measuring PIVKA-II in a sample by carrying out an immunoassay using antibodies comprising (a) an anti-PIVKA-II antibody that specifically binds to PIVKA-II or an antigen-binding fragment thereof and (b) a mixture of (i) an anti-F1 antibody that specifically binds to prothrombin fragment 1 or an antigen-binding fragment thereof and (ii) an anti-F2 antibody that specifically binds to prothrombin fragment 2 or an antigen-binding fragment thereof,

wherein said anti-F1 antibody, said anti-F2 antibody, and said anti-PIVKA-II antibody are monoclonal antibodies,

wherein the mixture of the anti-F1 antibody and the anti-F2 antibody is in a mixing ratio of 1:0.2-2,

wherein the immunoassay is a sandwich immunoassay using said mixture as a labeled antibody and said anti-PIVKA-II antibody as an immobilized antibody, or using said mixture as an immobilized antibody and said anti-PIVKA-II antibody as the labeled antibody, and

wherein said sample is serum or plasma.

2. The method according to claim 1 , wherein said anti-F1 antibody is an antibody that recognizes an epitope in the F1 region and binds to PIVKA-II, and said anti-F2 antibody is an antibody that recognizes an epitope in the F2 region and binds to PIVKA-II.

3. The method according to claim 1 , wherein said immunoassay is carried out by a sandwich method using said mixture as a labeled antibody and said anti-PIVKA-II antibody or antigen-binding fragment thereof as an immobilized antibody.

4. The method according to claim 1 , wherein the mixture ratio between said anti-F1 antibody or the antigen-binding fragment thereof and said anti-F2 antibody or the antigen-binding fragment thereof is a weight ratio of 1:0.5-1.0.

5. The method according to claim 1 , wherein said immunoassay has a serum-plasma ratio of 95% to 113%.

6. The method according to claim 1 , wherein the mixture of the anti-F1 antibody and the anti-F2 antibody is in a mixing ratio of 1:0.2-0.5.

Assignments (2)
MERGER Recorded Jan 19, 2018
From: EIDIA CO., LTD.
To: SEKISUI MEDICAL CO., LTD.
Reel/Frame 045096/0653 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 9, 2015
From: YAMAGUCHI, KENTARO; AOYAGI, KATSUMI; TERAO, AZUSA
To: FUJIREBIO INC.; EIDIA CO., LTD.
Reel/Frame 034915/0823 →
Priority Claims (1)
JP 2012-176761 · Aug 9, 2012 · national
Continuity (1)
Related Publication 20150219638A1 · Aug 6, 2015
Cited By (1)
US 12,351,647